Delivering The Next Generation of Complement Therapeutics
Ra Pharma combines novel insights into complement and other innate immunity pathways with leadership in macrocycle technology to transform the lives of patients with life threatening disorders. Ra’s proprietary peptide chemistry platform delivers drugs with the diversity and specificity of antibodies coupled with the pharmacological properties of small molecules. Our primary clinical focus is on diseases of complement dysregulation and orphan indications defined by validated biomarkers.
Ra Pharmaceuticals Announces $58.5M Series B Financing. Complement C5 Inhibitor Peptide Poised to Enter Clinical Evaluation for Paroxysmal Nocturnal Hemoglobinuria. Multi-target Collaboration with Merck Extended. More »
Kristopher Josephson, PhD, Senior Director, Discovery Research, presented at the Next Generation Protein Summit, May 18-20, 2015 in San Francisco
Ra Pharmaceuticals Announces Presentation of Data Supporting Clinical Development of Novel Complement C5 Inhibitor at 2014 ASH Annual Meeting More »
Ra Pharmaceuticals Appoints Pamela Esposito, PhD, as Chief Business Officer More »
Ra Pharmaceuticals Announces Broad Collaboration with Merck to Develop Cyclomimetics™. More »
Dr. Douglas Treco, CEO and Dr. Jack W. Szostak discuss their upcoming talks at the Inaugural Constrained Peptides and Macrocyclics Drug Discovery Conference. More »